Patent Application: Reducing DPP-4 Activity Using Plants

ChangeBridge: Patent Apps - Therapeutics (A61P)

Published September 26th, 2024

Detected March 26th, 2026

Summary

The USPTO has published a new patent application (US20260083804A1) detailing methods and compositions for reducing DPP-4 activity using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, aims to provide health benefits such as increased GLP-1 levels and reduced visceral fat.

View original document View source feed page

What changed

This document is a publication of a patent application filed with the USPTO, specifically application US20260083804A1. The application describes methods and compositions utilizing specific plants (Dichrostachys glomerata or Cissus quadrangularis) to reduce Dipeptidyl Peptidase-4 (DPP-4) activity or levels in mammals. Potential health benefits include increased GLP-1 levels, reduced visceral fat, and improved blood lipid and glucose profiles.

As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future developments in therapeutic approaches for conditions related to DPP-4 activity, such as type 2 diabetes. Companies involved in pharmaceutical research and development, particularly in the areas of metabolic disorders and natural product-based therapeutics, should monitor the progress of this and similar patent applications.

Source document (simplified)

← USPTO Patent Applications

METHODS AND COMPOSITIONS FOR REDUCING DPP-4 ACTIVITY OR LEVELS IN A MAMMAL USING NATURALLY OCCURING PLANTS AND SPICES

Application US20260083804A1 Kind: A1 Mar 26, 2026

Inventors

Shil Kothari, Julius Enyoug Oben

Abstract

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease DPP-4 activity or levels, visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing or decreasing DPP-4 activity or levels in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.